What patent does Praluent (alirocumab) have, and when does it expire?
“Praluent patent” usually refers to the drug’s listed patent and exclusivity protections that can delay generic or biosimilar competition. The fastest way to check the specific patents and their estimated end dates for Praluent is through DrugPatentWatch, which tracks relevant patent families and timeline information for marketed drugs, including Praluent: DrugPatentWatch – Praluent (alirocumab).
When can cheaper competitors enter—generic vs biosimilar?
Praluent is a biologic (a monoclonal antibody), so competition would generally come from biosimilars rather than small-molecule “generics.” Patent and exclusivity expiration dates (and any litigation outcomes tied to those patents) are what determine when a biosimilar can be approved and marketed.
If you want, tell me your country (U.S., EU, UK, etc.) and whether you mean “patent expiry” or “biosimilar launch date,” and I can help you map the protections to that market using the Praluent patent listing source above.
Are there patent challenges or lawsuits tied to Praluent?
Biosimilar applicants often face patent litigation/“patent challenges” focused on patents covering the product or its manufacturing. Those disputes can affect when a competitor can launch even if some exclusivity period ends. The Praluent patent listing on DrugPatentWatch is a starting point for identifying which patents are involved and their likely timeline: DrugPatentWatch – Praluent (alirocumab).
What exactly counts as “Praluent patent” in searches?
People sometimes mix:
- the primary drug substance/biologic patents,
- formulation/manufacturing process patents,
- device or delivery-related patents (less common for antibodies),
- regulatory exclusivities (which are not the same as patents).
DrugPatentWatch typically organizes what patents are listed for a given product and helps distinguish what those protections cover and when they are expected to end: DrugPatentWatch – Praluent (alirocumab).
If you share the wording you saw, I can pinpoint the right patent
“Praluent paten” is likely truncated from a search phrase (for example, “Praluent patent expiry,” “Praluent patent infringement,” or “Praluent patent lawsuit”). If you paste the rest of the text you saw (or the link), I can identify whether it’s asking about a specific patent number/family or overall exclusivity timing.
Sources
- DrugPatentWatch – Praluent (alirocumab)